Sherry Mansour, MD, MS
DownloadHi-Res Photo
Cards
Appointments
Nephrology
Primary
Contact Info
Clinical and Translational Research Accelerator (CTRA)
60 temple st
New Haven, Connecticut 05613
United States
About
Titles
Assistant Professor
Biography
Dr. Sherry Mansour grew up and attended medical school in New York. She graduated in 2010 and received the Highest Academic Achievement Award. She was elected valedictorian of her class and was also inducted into the Psi Sigma Alpha National Osteopathic Scholastic Honor Society. She went on to complete residency training in Internal Medicine at Stony Brook University Medical Center, where she was chosen as chief medical resident. She was inducted into the Alpha Omega Alpha Honor Medical Society, Stony Brook Chapter in 2012. She then joined Yale New Haven Hospital in 2014 as a Clinical Research Nephrology fellow. She also completed her Master of Science from the Yale School of Public Health in 2019 with a focus on Chronic Disease Epidemiology. Since her arrival at Yale, Dr. Mansour has been working on identifying novel repair biomarkers in blood and urine to better predict long-term kidney and heart disease outcomes after AKI, and improve overall patient care. Her K-23 proposal is focused on understanding the role of a vessel repair pathway, known as the Angiopoietin pathway, in graft outcomes after deceased donor kidney transplantation.
Appointments
Nephrology
Assistant ProfessorPrimary
Other Departments & Organizations
Education & Training
- MS
- Yale University, Clinical Disease Epidemiology and Biostatistics (2019)
- Nephrology Clinical Research Fellowship
- Yale New Haven Hospital (2018)
- Research Fellow, Nephrology
- Yale School of Medicine (2018)
- Clinical Fellow, Nephrology
- Yale School of Medicine (2016)
- Internal Medicine Chief Residency
- Stony Brook University Hospital (2014)
- Internal Medicine Residency
- Stony Brook University Hospital (2013)
- MD
- NYCOM (2010)
- DO
- New York College of Osteopathic Medicine, Osteopathic Medicine
- BS
- New York Institute of Technology, Osteopathic Medicine (2007)
Board Certifications
Nephrology
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 2016
Internal Medicine
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 2013
Research
Overview
Dr. Mansour uses translational and epidemiological research methods to characterize the role of repair biomarkers in the development of long-term outcomes in patients with acute kidney injury.
Dr. Mansour was the recipient of T32-DK7276-40 Institutional Grant (T32) from the National Institute of Diabetes, Digestive, and Kidney Diseases (NIDDK), as well as a Career Development Grant (18CDA34110151) from the American Heart Association (AHA), Robert Leet Patterson and Clara Guthrie Patterson Trust Mentored Research Award, O'Brien Kidney Pilot Grant and NIH/NIDDK K23 award.
Current Research Projects:
Role of Repair Biomarkers in Predicting Cardiac and Renal Outcomes in Hospitalized Patients
Role of Vascular Repair Biomarkers in Understanding Recipient Graft Outcomes.
Phenotyping Deceased Donor AKI to Predict Graft Outcomes.
Understanding AKI and recovery in Marathon Runners.
ORCID
0000-0001-7837-0165
Research at a Glance
Yale Co-Authors
Frequent collaborators of Sherry Mansour's published research.
Publications Timeline
A big-picture view of Sherry Mansour's research output by year.
Dennis G Moledina, MD, PhD, FASN
F. Perry Wilson, MD, MSCE
Jeffrey Testani, MD, MTR
Fan Li, PhD
Joe El-Khoury, PhD, DABCC, FACB
Michael Simonov, MD
56Publications
1,107Citations
Publications
2024
Kidney Transplant Outcomes From Deceased Donors Who Received Dialysis
Wen Y, Mansour S, Srialluri N, Hu D, Philbrook H, Hall I, Doshi M, Mohan S, Reese P, Parikh C. Kidney Transplant Outcomes From Deceased Donors Who Received Dialysis. JAMA 2024, 332: 215-225. PMID: 38780515, PMCID: PMC11117155, DOI: 10.1001/jama.2024.8469.Peer-Reviewed Original ResearchCitationsAltmetricConceptsDeath-censored graft failureKidney transplant recipientsGraft failureDeceased kidney donorsKidney transplantationTransplant recipientsGraft functionDeceased donorsFollow-upHigher risk of delayed graft functionIncidence of delayed graft functionOutcomes of transplant recipientsRisk of delayed graft functionMedian follow-upKidney donorsDelayed graft functionUS organ procurement organizationsKidney transplant outcomesRetrospective cohort studyRecipients of kidneysKidney donationThe Role of Angiopoietins in Cardiovascular Outcomes of Kidney Transplant Recipients- An Ancillary Study From the FAVORIT.
Gendy N, Brown L, Staunton M, Garg K, Hernandez Garcilazo N, Qian L, Yamamoto Y, Ugwuowo U, Obeid W, Al-Qusairi L, Bostom A, Mansour S. The Role of Angiopoietins in Cardiovascular Outcomes of Kidney Transplant Recipients- An Ancillary Study From the FAVORIT. American Journal Of Nephrology 2024 PMID: 38735283, DOI: 10.1159/000538878.Peer-Reviewed Original ResearchAltmetricConceptsKidney transplant recipientsRisk of cardiovascular diseaseGraft failureCardiovascular disease developmentAngpt-2Cardiovascular diseaseIncreased risk of future CVDAncillary studiesClinical variablesCare of kidney transplant recipientsIncreased riskRisk of future CVDUrine albumin-to-creatinine ratioDonor kidney transplant recipientsAlbumin-to-creatinine ratioIncreased risk of cardiovascular diseaseFuture cardiovascular diseaseImproves prediction of cardiovascular diseaseTransplant-related variablesAssociated with outcomeParticipants' median ageMitigate CVD riskMedian ageTransplant recipientsMedian time
2023
Analysis of the human kidney transcriptome and plasma proteome identifies markers of proximal tubule maladaptation to injury
Wen Y, Su E, Xu L, Menez S, Moledina D, Obeid W, Palevsky P, Mansour S, Devarajan P, Cantley L, Cahan P, Parikh C, Project K, Injury T. Analysis of the human kidney transcriptome and plasma proteome identifies markers of proximal tubule maladaptation to injury. Science Translational Medicine 2023, 15: eade7287. PMID: 38091407, DOI: 10.1126/scitranslmed.ade7287.Peer-Reviewed Original ResearchCitationsAltmetricPrediction of Postdischarge Kidney Disease Progression Among Patients with Hospitalized AKI: The ASSESS-AKI Study
Menez S, Kerr K, Cheng S, Hu D, Philbrook H, Moledina D, Mansour S, Go A, Ikizler T, Kaufman J, Kimmel P, Himmelfarb J, Coca S, Parikh C. Prediction of Postdischarge Kidney Disease Progression Among Patients with Hospitalized AKI: The ASSESS-AKI Study. Journal Of The American Society Of Nephrology 2023, 34: 62-62. DOI: 10.1681/asn.20233411s162a.Peer-Reviewed Original ResearchAssociation of Post-Hospitalization Vascular Biomarker Clusters with Future Heart Failure
Shi A, Andrawis A, Obeid W, Go A, Liu K, Wurfel M, Himmelfarb J, Parikh C, Bhatraju P, Chinchilli V, Kimmel P, Kaufman J, Coca S, Reeves W, Garg A, Siew E, Ikizler T, Philbrook H, Hsu C, Prince D, Wilson F, Mansour S. Association of Post-Hospitalization Vascular Biomarker Clusters with Future Heart Failure. Journal Of The American Society Of Nephrology 2023, 34: 61-61. DOI: 10.1681/asn.20233411s161a.Peer-Reviewed Original ResearchRole of Angiopoietins in Cardiovascular Disease (CVD) Outcomes of Kidney Transplant Recipients
Brown L, Gendy N, Staunton M, Garg K, Yamamoto Y, Obeid W, Bostom A, Mansour S. Role of Angiopoietins in Cardiovascular Disease (CVD) Outcomes of Kidney Transplant Recipients. Journal Of The American Society Of Nephrology 2023, 34: 319-320. DOI: 10.1681/asn.20233411s1319c.Peer-Reviewed Original ResearchImproving the Odds—COVID-Omics and Predicting Patient Outcomes
Shi A, Mansour S. Improving the Odds—COVID-Omics and Predicting Patient Outcomes. Current Transplantation Reports 2023, 10: 126-134. DOI: 10.1007/s40472-023-00403-7.Peer-Reviewed Original ResearchConceptsPublic health agenciesHealth agenciesRisk stratification criteriaPatient risk stratificationCOVID-19 patientsPublic health surveillanceImmunosuppression regimensTargetable biomarkersRisk stratificationClinician recommendationsPatient outcomesPredicting Patient OutcomeNext pandemicHealth surveillanceSummaryThis reviewMillions of livesTransplant researchersViral pathwaysCOVID-19 pandemicPathway analysisPharmaceutical companiesGlobal COVID-19 pandemicPandemicRegimensPatientsThe Role of Vascular Biomarkers in Outcomes of Patients with Kidney Disease
Shi A, Mansour S. The Role of Vascular Biomarkers in Outcomes of Patients with Kidney Disease. Nephron 2023, 147: 778-781. PMID: 37611550, PMCID: PMC10841333, DOI: 10.1159/000533415.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsAcute kidney injuryAngpt-2 levelsCardiovascular diseaseVascular biomarkersPoor outcomeChronic kidney disease patientsPoor long-term outcomesGrowth factorKidney transplant recipientsOutcomes of patientsKidney disease progressionKidney disease patientsLong-term outcomesPlacental growth factorVascular endothelial growth factorEndothelial growth factorAKI patientsAKI survivorsCardiac complicationsKidney injuryTransplant recipientsCardiac surgeryHeart failureHospitalized patientsEndothelial damageA randomized clinical trial assessing the effect of automated medication-targeted alerts on acute kidney injury outcomes
Wilson F, Yamamoto Y, Martin M, Coronel-Moreno C, Li F, Cheng C, Aklilu A, Ghazi L, Greenberg J, Latham S, Melchinger H, Mansour S, Moledina D, Parikh C, Partridge C, Testani J, Ugwuowo U. A randomized clinical trial assessing the effect of automated medication-targeted alerts on acute kidney injury outcomes. Nature Communications 2023, 14: 2826. PMID: 37198160, PMCID: PMC10192367, DOI: 10.1038/s41467-023-38532-3.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsAcute kidney injuryUsual care groupKidney injuryCare groupAcute Kidney Injury OutcomesAlert groupNon-steroidal anti-inflammatory drugsComposite of progressionHours of randomizationMedications of interestAldosterone system inhibitorsClasses of medicationsProton pump inhibitorsRandomized clinical trialsAnti-inflammatory drugsClinical decision support systemNephrotoxic medicationsHospitalized adultsDiscontinuation ratesCertain medicationsPrimary outcomeSubstantial morbiditySystem inhibitorsPump inhibitorsParallel groupIntegrated Analysis of Blood and Urine Biomarkers to Identify Acute Kidney Injury Subphenotypes and Associations With Long-term Outcomes
Bhatraju P, Prince D, Mansour S, Ikizler T, Siew E, Chinchilli V, Garg A, Go A, Kaufman J, Kimmel P, Coca S, Parikh C, Wurfel M, Himmelfarb J. Integrated Analysis of Blood and Urine Biomarkers to Identify Acute Kidney Injury Subphenotypes and Associations With Long-term Outcomes. American Journal Of Kidney Diseases 2023, 82: 311-321.e1. PMID: 37178093, PMCID: PMC10523857, DOI: 10.1053/j.ajkd.2023.01.449.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsMajor adverse kidney eventsLong-term outcomesAKI subphenotypesKidney injuryClinical outcomesUrinary biomarkersHigh riskChronic kidney disease progressionLong-term clinical outcomesCox proportional hazards modelAdverse kidney eventsLong-term sequalaeHospital-level factorsKidney disease progressionChronic kidney diseaseKaplan-Meier curvesSerum creatinine concentrationEpithelial cell injuryHeterogeneous clinical syndromeProportional hazards modelLong-term riskAKI patientsAKI subgroupKDIGO stageMedian follow
Academic Achievements and Community Involvement
activity Member
Professional OrganizationsAmerican Society of NephrologyDetails2014 - Presentactivity Member
Professional OrganizationsAmerican College of PhysiciansDetails2013 - Presentactivity Member
Professional OrganizationsAmerican Heart AssociationDetails2017 - Presentactivity Member
Professional OrganizationsInternational Society of NephrologyDetails2018 - Presentactivity Member
Professional OrganizationsAmerican Transplant CongressDetails2015 - Present
Links & Media
News
Get In Touch
Contacts
Mailing Address
Clinical and Translational Research Accelerator (CTRA)
60 temple st
New Haven, Connecticut 05613
United States